Change over period: —
NSE · ORCHPHARMA
ORCHPHARMA
-13.7% from the 52-week high · +98.1% above the low
Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
The short version. ORCHPHARMA reported revenue of ₹341 crore for Sep 2026, up 75.8% from a year earlier. Net profit was ₹29 crore. Return on equity was 0.6% in Mar 2026. Promoter holding was 74.45% in Sep 2026, up 4.61 points over 8 quarters.
1 · The price
How has the stock traded?
ORCHPHARMA trades 13.7% below its 52-week high and 98.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹341 cr.
11.4 pts higher than a year earlier.
Revenue compounded at 22.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 341 | 304 | 368 | 207 | 194 | 173 | 237 | 217 |
| Net profit | 29 | 3 | 26 | -13 | -6 | 15 | 22 | 21 |
| Net margin % | 8.4 | 1.1 | 7.0 | -6.1 | -3.0 | 8.6 | 9.4 | 9.6 |
| EPS (₹) | 4.77 | 0.64 | 5.09 | -2.49 | -1.13 | 2.94 | 4.4 | 4.1 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1233 | 922 | 819 | 666 | 560 | 450 | 508 | 600 |
| Net profit | 10 | 100 | 92 | 46 | -2 | -117 | -131 | 69 |
| Net margin % | 0.8 | 10.8 | 11.2 | 7.0 | -0.3 | -25.9 | -25.8 | 11.6 |
| EPS (₹) | 1.96 | 19.65 | 18.17 | 11.35 | -0.48 | -28.55 | -32.11 | 7.8 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 0.6% in Mar 2026; debt to equity is 0.19.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 0.6 | 7.9 | 7.9 | 6.7 |
| Return on capital % | 1.1 | 7.8 | 8.4 | 10.2 |
| EBITDA margin % | 4.9 | 15.2 | 16.7 | 20.8 |
| Net margin % | 0.8 | 10.5 | 10.8 | 6.8 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 22.8% | 22.2% |
| Profit CAGR | -40.1% | — |
4 · The owners
Who holds it, and are they adding?
Up 4.61 pts over 8 quarters.
Down 1.6 pts over 8 quarters.
Down 1.55 pts over 8 quarters.
+2 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 69.84 | 69.84 | 69.84 | 69.84 | 69.84 | 69.84 | 69.84 | 74.45 | +4.61 |
| FII | 2.53 | 2.69 | 1.4 | 1.56 | 1.17 | 0.87 | 0.81 | 0.93 | -1.6 |
| DII | 18.99 | 20.1 | 19.43 | 19.04 | 19.39 | 20.25 | 20.75 | 17.44 | -1.55 |
| Public | 8.64 | 7.38 | 9.34 | 9.57 | 9.6 | 9.05 | 8.61 | 7.18 | -1.46 |
Mutual fund holdings · Oct 2026
27 schemes hold this stock
25 the month before.
- Kotak Special Opportunities Fund2.36% of NAV
- Kotak Consumption Fund1.48% of NAV
- Kotak Healthcare Fund1.26% of NAV
- UTI Value Fund1.1% of NAV
- Kotak MNC Fund1.03% of NAV
- TATA INDIA INNOVATION FUND0.98% of NAV
- Bandhan Healthcare Fund0.95% of NAV
- quant Small Cap Fund0.86% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ORCHPHARMA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ORCHPHARMA
What is the ORCHPHARMA share price?
ORCHPHARMA (ORCHPHARMA) last closed at ₹948.60, down 0.77% on the day. Its 52-week range is ₹482.45 to ₹1,107.20.
What is the market cap of ORCHPHARMA?
ORCHPHARMA has a market capitalisation of about ₹5,721 crore.
How are ORCHPHARMA's latest results?
ORCHPHARMA reported revenue of ₹341 crore for Sep 2026, up 75.8% from a year earlier. Net profit was ₹29 crore. Return on equity was 0.6% in Mar 2026. Promoter holding was 74.45% in Sep 2026, up 4.61 points over 8 quarters.
Who owns ORCHPHARMA?
As of Sep 2026, shareholding was: Promoter 74.45%, FII 0.93%, DII 17.44%, Public 7.18%.
How many mutual funds hold ORCHPHARMA?
27 mutual fund schemes held ORCHPHARMA in October 2026. That compares with 25 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.